Structure-Based Drug Design to the Discovery of New 2-Aminothiazole Cdk2 Inhibitors.
Vulpetti, A., Casale, E., Roletto, F., Amici, R., Villa, M., Pevarello, P.(2006) J Mol Graph Model 24: 341
- PubMed: 16260160 
- DOI: https://doi.org/10.1016/j.jmgm.2005.09.012
- Primary Citation of Related Structures:  
2BTR, 2BTS - PubMed Abstract: 
N-(5-Bromo-1,3-thiazol-2-yl)butanamide (compound 1) was found active (IC50=808 nM) in a high throughput screening (HTS) for CDK2 inhibitors. By exploiting crystal structures of several complexes between CDK2 and inhibitors and applying structure-based drug design (SBDD), we rapidly discovered a very potent and selective CDK2 inhibitor 4-[(5-isopropyl-1,3-thiazol-2-yl)amino] benzenesulfonamide (compound 4, IC50=20 nM). The syntheses, structure-based analog design, kinases inhibition data and X-ray crystallographic structures of CDK2/inhibitor complexes are reported.
Organizational Affiliation: 
Department of Chemistry, Nerviano Medical Sciences, Discovery Research Oncology, Viale Pasteur 10, 20014 Nerviano (MI), Italy. anna.vulpetti@nervianoms.com